HC Wainwright reaffirmed their buy rating on shares of Caladrius Biosciences, Inc. (NASDAQ:CLBS) in a report issued on Friday. The firm currently has a $7.00 price objective on the biotechnology company’s stock.
Several other research analysts have also recently weighed in on CLBS. Zacks Investment Research raised Caladrius Biosciences from a sell rating to a hold rating in a research report on Wednesday, July 19th. ValuEngine raised Caladrius Biosciences from a strong sell rating to a sell rating in a research report on Friday, September 1st.
Caladrius Biosciences (NASDAQ CLBS) traded down $0.12 during mid-day trading on Friday, reaching $3.01. The company’s stock had a trading volume of 25,300 shares, compared to its average volume of 59,040. Caladrius Biosciences has a twelve month low of $2.63 and a twelve month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 141.14% and a negative net margin of 84.10%. equities analysts expect that Caladrius Biosciences will post -2.73 EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of CLBS. Renaissance Technologies LLC lifted its position in shares of Caladrius Biosciences by 34.3% during the 1st quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 24,900 shares during the last quarter. KCG Holdings Inc. lifted its position in shares of Caladrius Biosciences by 74.6% during the 1st quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 15,501 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Caladrius Biosciences by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after buying an additional 4,163 shares during the last quarter. 6.36% of the stock is currently owned by hedge funds and other institutional investors.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.